Inside the Histocompatibility Lab: Transplantation's Hidden Safeguard

Before any transplant happens, a histocompatibility laboratory performs the testing that determines whether a donor and recipient are compatible. Here is how these labs work and why they matter.

Most patients know their surgeon's name. Few know the name of their histocompatibility laboratory director. Yet the work done in these labs is among the most consequential in the transplant process.

Histocompatibility laboratories perform the HLA typing, antibody screening, and crossmatch testing that determine whether a given donor is compatible with a given recipient. Their results directly influence which patients receive which organs and how the post-transplant immunosuppression protocol is designed.

What histocompatibility labs do

The core functions of a histocompatibility lab fall into three categories:

HLA typing. The lab determines the HLA alleles carried by both donors and recipients. Modern typing methods use DNA-based techniques (primarily sequence-based typing and next-generation sequencing) to identify HLA alleles at high resolution. This is a significant advance over earlier serological methods, which could only distinguish broad HLA groups.

Antibody screening and identification. Many transplant candidates, particularly those who have had previous transplants, blood transfusions, or pregnancies, develop antibodies against specific HLA molecules. The lab tests the patient's serum to identify which HLA molecules these antibodies target. Donors whose HLA molecules match those targets are generally avoided because the preformed antibodies can cause hyperacute or accelerated rejection.

Crossmatching. Before a transplant proceeds, the lab performs a crossmatch test that mixes the recipient's serum with donor cells. A positive crossmatch, meaning the recipient has antibodies that react with the donor's cells, is typically a contraindication to transplantation.

The expertise behind the results

Histocompatibility is a specialized field that sits at the intersection of immunology, genetics, and laboratory medicine. Lab directors are typically certified by the American College of Histocompatibility and Immunogenetics (ACHI) — the certifying body formed in 2020 from the merger of the former American Board of Histocompatibility and Immunogenetics (ABHI) with ASHI's director training, review, and credentialing committee — and have extensive training in transplant immunology.

The interpretive work these professionals do is significant. A list of HLA mismatches and antibody specificities does not interpret itself. The lab director must assess whether a specific antibody is clinically significant, whether a crossmatch result is a true positive or an artifact, and how the overall immunological risk profile should be communicated to the transplant team.

Where technology can help

Histocompatibility laboratories are natural partners for AI-based compatibility tools. The lab is where HLA data is generated, antibody profiles are maintained, and compatibility assessments are made. Any tool that aims to improve matching precision must integrate into the lab's existing workflow.

At Immunomatics, we see histocompatibility laboratories as our primary end users. We’re developing a platform that generates risk estimates designed to complement, not replace, the interpretive expertise that lab directors bring to each case. The goal is to put better information in the hands of the people who are already making these critical assessments.